» Articles » PMID: 20111912

The Clinical Characteristics of CD7+ CD56+ Acute Myeloid Leukemias Other Than M0

Overview
Journal Int J Hematol
Specialty Hematology
Date 2010 Jan 30
PMID 20111912
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Immunological phenotyping of acute leukemia have provided enormous and important information for the classification and lineage determination of leukemia. Forty-nine patients with CD7(+) CD56(+) acute myeloid leukemia (AML) were analyzed. There were 17 patients of M0, which corresponded to myeloid/NK cell precursor acute leukemia, and 32 patients of AML other than M0 (9 each for M1 and M2, one for M3, 3 for M4, 4 for M5 and 6 for M7). Age distribution was similar between these two groups, but CD7(+) CD56(+) M0 showed significant male predominance than CD7(+) CD56(+) M1-M7 (M:F = 15:2 vs. 15:17, P = 0.006). The disease localization and the hematological manifestations were different, showing fewer white blood cell counts and circulating leukemic blasts, less anemia, less thrombocytopenia and more frequent extramedullary involvement in M0 group. The prognosis was poor in both groups, and there was no statistical difference. These findings suggest that extramedullary involvement of myeloid/NK cell precursor acute leukemia is not directly derived from the presence of CD7 and CD56 antigens on leukemic cells. The poor prognosis of CD7(+) CD56(+) M1-M7 suggests that this phenotype may act as a prognostic factor for AML, but this should be confirmed in further studies.

Citing Articles

Acute myeloid leukemia with a :: fusion gene following chemotherapy and radiotherapy for breast cancer: A case report.

Kawai H, Shiraiwa S, Ogiya D, Toyosaki M, Machida S, Suzuki R Leuk Res Rep. 2024; 22:100478.

PMID: 39258225 PMC: 11385777. DOI: 10.1016/j.lrr.2024.100478.


Prevalence and clinical impact of CD56 and T-cell marker expression in acute myeloid leukaemia: A single-centre retrospective analysis.

Shaforostova I, Call S, Evers G, Reicherts C, Angenendt L, Stelljes M EJHaem. 2024; 5(1):93-104.

PMID: 38406551 PMC: 10887264. DOI: 10.1002/jha2.827.


MRD abnormal expression predict poor outcomes for refractory or relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.

Hao Q, Liu X, Zhang Y, Zhang D, Li B, Wang J J Clin Lab Anal. 2021; 35(10):e23974.

PMID: 34432318 PMC: 8529132. DOI: 10.1002/jcla.23974.


A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma.

Atrash S, Moyo T Onco Targets Ther. 2021; 14:2185-2201.

PMID: 33814917 PMC: 8009535. DOI: 10.2147/OTT.S242018.


Prognostic significance of CD56 and CD7 in acute myeloid leukaemia and their outcome.

Rai S, Singh S, Gupta R Am J Blood Res. 2020; 10(4):109-117.

PMID: 32923090 PMC: 7486483.


References
1.
Suzuki R, Murata M, Kami M, Ohtake S, Asou N, Kodera Y . Prognostic significance of CD7+CD56+ phenotype and chromosome 5 abnormalities for acute myeloid leukemia M0. Int J Hematol. 2003; 77(5):482-9. DOI: 10.1007/BF02986617. View

2.
Bennett J, Catovsky D, Daniel M, Flandrin G, GALTON D, Gralnick H . Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976; 33(4):451-8. DOI: 10.1111/j.1365-2141.1976.tb03563.x. View

3.
Syrjala M, Anttila V, Ruutu T, Jansson S . Flow cytometric detection of residual disease in acute leukemia by assaying blasts co-expressing myeloid and lymphatic antigens. Leukemia. 1994; 8(9):1564-70. View

4.
Murray C, Estey E, Paietta E, Howard R, Edenfield W, Pierce S . CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome?. J Clin Oncol. 1999; 17(1):293-7. DOI: 10.1200/JCO.1999.17.1.293. View

5.
Sanchez M, Muench M, Roncarolo M, Lanier L, Phillips J . Identification of a common T/natural killer cell progenitor in human fetal thymus. J Exp Med. 1994; 180(2):569-76. PMC: 2191594. DOI: 10.1084/jem.180.2.569. View